Abstract
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose aspirin is accompanied by risk of upper and lower gastrointestinal (GI) complications, some of which can be serious or even fatal. Management strategies to reduce this risk include gastroprotective pharmacotherapy, use of safer NSAIDs, and eradication of Helicobacter pylori infection. In this article, Dr Lanas summarizes the GI risks associated with NSAID and low-dose aspirin therapy and weighs the efficacy of current risk management strategies.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
-
Anti-Inflammatory Agents, Non-Steroidal / adverse effects*
-
Anti-Inflammatory Agents, Non-Steroidal / therapeutic use
-
Aspirin / administration & dosage
-
Aspirin / adverse effects
-
Cyclooxygenase Inhibitors / administration & dosage
-
Cyclooxygenase Inhibitors / adverse effects
-
Dyspepsia / chemically induced
-
Gastrointestinal Hemorrhage / chemically induced*
-
Gastrointestinal Hemorrhage / microbiology
-
Gastrointestinal Hemorrhage / prevention & control
-
Gastrointestinal Tract / drug effects
-
Helicobacter Infections / complications
-
Helicobacter Infections / drug therapy
-
Helicobacter pylori
-
Humans
-
Peptic Ulcer / microbiology
-
Peptic Ulcer Hemorrhage / chemically induced
-
Peptic Ulcer Hemorrhage / prevention & control
-
Peptic Ulcer Perforation / chemically induced
-
Peptic Ulcer Perforation / prevention & control
-
Proton Pump Inhibitors
-
Risk Assessment
-
Risk Factors
Substances
-
Anti-Inflammatory Agents, Non-Steroidal
-
Cyclooxygenase Inhibitors
-
Proton Pump Inhibitors
-
Aspirin